DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Svb Leerink lifted their Q4 2019 EPS estimates for shares of DexCom in a report issued on Wednesday, November 6th. Svb Leerink analyst D. Antalffy now forecasts that the medical device company will post earnings per share of $0.88 for the quarter, up from their prior forecast of $0.83. Svb Leerink also issued estimates for DexCom’s FY2020 earnings at $2.14 EPS.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. During the same quarter in the prior year, the company earned $0.17 EPS. DexCom’s revenue was up 48.6% on a year-over-year basis.
DXCM opened at $198.08 on Friday. DexCom has a 12-month low of $105.05 and a 12-month high of $200.80. The firm has a market cap of $14.00 billion, a price-to-earnings ratio of 660.27 and a beta of 0.64. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56. The stock’s 50-day moving average price is $155.57 and its 200 day moving average price is $146.29.
In related news, EVP Steven Robert Pacelli sold 1,532 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $155.47, for a total value of $238,180.04. Following the completion of the sale, the executive vice president now directly owns 66,821 shares of the company’s stock, valued at approximately $10,388,660.87. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $156.12, for a total value of $1,561,200.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 105,222 shares of company stock valued at $16,407,406. Insiders own 1.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of DXCM. Gradient Investments LLC acquired a new stake in DexCom during the 2nd quarter worth approximately $25,000. Virtus ETF Advisers LLC acquired a new stake in DexCom during the 2nd quarter worth approximately $29,000. Steward Partners Investment Advisory LLC acquired a new stake in DexCom during the 2nd quarter worth approximately $31,000. CSat Investment Advisory L.P. acquired a new stake in DexCom during the 2nd quarter worth approximately $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in DexCom during the 2nd quarter worth approximately $37,000. 96.19% of the stock is owned by institutional investors.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Technical Analysis
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.